Lynx1 Capital Management as of Dec. 31, 2025
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 22 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Stoke Therapeutics (STOK) | 34.7 | $172M | 5.4M | 31.74 | |
| Gh Research Ordinary Shares (GHRS) | 26.8 | $132M | 10M | 12.70 | |
| Cullinan Oncology (CGEM) | 18.8 | $93M | 9.0M | 10.35 | |
| Denali Therapeutics (DNLI) | 5.8 | $29M | 1.7M | 16.51 | |
| C4 Therapeutics Com Stk (CCCC) | 2.7 | $14M | 7.1M | 1.91 | |
| Xencor (XNCR) | 2.2 | $11M | 706k | 15.31 | |
| Immatics SHS (IMTX) | 2.0 | $9.7M | 922k | 10.50 | |
| Tscan Therapeutics (TCRX) | 1.6 | $8.0M | 8.0M | 1.00 | |
| Passage Bio Com New (PASG) | 1.5 | $7.4M | 624k | 11.80 | |
| Korro Bio (KRRO) | 1.1 | $5.4M | 678k | 8.01 | |
| Precision Biosciences Com New (DTIL) | 0.8 | $4.1M | 994k | 4.16 | |
| Neuphoria Therapeutics (NEUP) | 0.7 | $3.4M | 875k | 3.88 | |
| Agios Pharmaceuticals (AGIO) | 0.4 | $2.2M | 80k | 27.22 | |
| Cg Oncology (CGON) | 0.3 | $1.3M | 32k | 41.52 | |
| Arrowhead Pharmaceuticals (ARWR) | 0.2 | $800k | 12k | 66.39 | |
| Design Therapeutics (DSGN) | 0.1 | $652k | 70k | 9.38 | |
| Entrada Therapeutics (TRDA) | 0.1 | $531k | 52k | 10.28 | |
| Werewolf Therapeutics (HOWL) | 0.1 | $416k | 656k | 0.63 | |
| Maplight Therapeutics (MPLT) | 0.0 | $237k | 14k | 17.57 | |
| Generation Bio Com New (GBIO) | 0.0 | $142k | 25k | 5.68 | |
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.0 | $138k | 69k | 2.02 | |
| Applied Therapeutics | 0.0 | $41k | 411k | 0.10 |
